Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongin Cho

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Endocrinology and Metabolism (Seoul, Korea)|November 7, 2023
Familial Correlation and Heritability of Hand Grip Strength in Korean Adults (Korea National Health and Nutrition Examination Survey 2014 to 2019)Seong Hee Ahn, Eun Byeol Park, Seongha Seo, et al.
Plos One|February 7, 2025
The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillationYongin Cho, Sung-Hee Shin, Min-Ae Park, et al.
Diabetes & Metabolism Journal|January 29, 2019
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 InhibitorsJi Yeon Lee, Yongin Cho, Minyoung Lee, et al.
Scientific Reports|November 11, 2020
Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expressionMinyoung Lee, Eugene Shin, Jaehyun Bae, et al.
Medicine|September 10, 2022
Prediction of antidiabetic effect after gastrectomy with Roux-en-Y reconstruction in patients with gastric cancer and type 2 diabetesSeong Ha Seo, Yongin Cho, Yoon Seok Heo, et al.
BMC Medicine|March 21, 2022
Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)Yongin Cho, Hyungjin Rhee, Young-Eun Kim, et al.
Diabetes & Metabolism|October 18, 2022
Prevalence and risk of diabetic complications in young-onset versus late-onset type 2 diabetes mellitusYongin Cho, Hye-Sun Park, Byung Wook Huh, et al.
Journal of Clinical Medicine|August 3, 2019
Prevalence of Thyroid Disease in Patients Surgically Treated for Pituitary DiseaseDaham Kim, Yongin Cho, Cheol Ryong Ku, et al.
BMC Medicine|May 7, 2025
Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trialMinyoung Lee, Sukchul Hong, Yongin Cho, et al.
Yonsei Medical Journal|August 29, 2022
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical PracticeDa Hea Seo, Young Ju Suh, Yongin Cho, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Endocrinology and Metabolism (Seoul, Korea)|November 7, 2023
Familial Correlation and Heritability of Hand Grip Strength in Korean Adults (Korea National Health and Nutrition Examination Survey 2014 to 2019)Seong Hee Ahn, Eun Byeol Park, Seongha Seo, et al.
Plos One|February 7, 2025
The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillationYongin Cho, Sung-Hee Shin, Min-Ae Park, et al.
Diabetes & Metabolism Journal|January 29, 2019
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 InhibitorsJi Yeon Lee, Yongin Cho, Minyoung Lee, et al.
Scientific Reports|November 11, 2020
Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expressionMinyoung Lee, Eugene Shin, Jaehyun Bae, et al.
Medicine|September 10, 2022
Prediction of antidiabetic effect after gastrectomy with Roux-en-Y reconstruction in patients with gastric cancer and type 2 diabetesSeong Ha Seo, Yongin Cho, Yoon Seok Heo, et al.
BMC Medicine|March 21, 2022
Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)Yongin Cho, Hyungjin Rhee, Young-Eun Kim, et al.
Diabetes & Metabolism|October 18, 2022
Prevalence and risk of diabetic complications in young-onset versus late-onset type 2 diabetes mellitusYongin Cho, Hye-Sun Park, Byung Wook Huh, et al.
Journal of Clinical Medicine|August 3, 2019
Prevalence of Thyroid Disease in Patients Surgically Treated for Pituitary DiseaseDaham Kim, Yongin Cho, Cheol Ryong Ku, et al.
BMC Medicine|May 7, 2025
Synergistic benefit of thiazolidinedione and sodium-glucose cotransporter 2 inhibitor for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a 24-week, open-label, randomized controlled trialMinyoung Lee, Sukchul Hong, Yongin Cho, et al.
Yonsei Medical Journal|August 29, 2022
Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical PracticeDa Hea Seo, Young Ju Suh, Yongin Cho, et al.
Pageof 6